Best Practice and Research. Clinical Gastroenterology 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?
Publication date: Available online 22 February 2019Source: Best Practice & Research Clinical GastroenterologyAuthor(s): Christopher Ma, Robert Battat, Reena Khanna, Claire E. Parker, Brian G. Feagan, Vipul JairathAbstractHistorically, the evaluation of patients with Crohn's disease (CD) has centered on use of subjective symptom-based assessment. However, patients with CD experience a broad spectrum of non-specific symptoms that may not directly correlate with objective measures of inflammation. Endoscopy has been the gold standard for evaluating the burden and severity of mucosal disease. However, use of ileocolonoscopy fo...
Source: Best Practice and Research Clinical Gastroenterology - March 1, 2019 Category: Gastroenterology Source Type: research
IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?
Publication date: Available online 19 February 2019Source: Best Practice & Research Clinical GastroenterologyAuthor(s): Christopher Ma, Remo Panaccione, Reena Khanna, Brian G. Feagan, Vipul JairathAbstractThe interleukin (IL)-12 family of cytokines, including IL12 and IL 23, play an important role in driving aberrant Th1 and Th17 immune responses in patients with Crohn's disease (CD). Targeting this pathway has opened new avenues for therapeutic intervention. The approval of ustekinumab, a monoclonal antibody blocking the common p40 subunit of IL12 and IL23, marked an important evolution in medical management for CD: this ...
Source: Best Practice and Research Clinical Gastroenterology - February 26, 2019 Category: Gastroenterology Source Type: research
What is the role of histopathology in the evaluation of disease activity in Crohn's disease?
Publication date: Available online 15 February 2019Source: Best Practice & Research Clinical GastroenterologyAuthor(s): Rish K. Pai, Vipul JairathAbstractAssessment of disease activity is essential for developing and determining appropriate therapy in patients with Crohn's disease. Currently, clinical and endoscopic treatment targets have been proposed, whereas histologic assessment of disease activity is not recommended in expert guidelines. Histologic assessment of disease activity has emerged as an important tool in ulcerative colitis as persistent histological inflammation is associated with clinical relapse, corticost...
Source: Best Practice and Research Clinical Gastroenterology - February 22, 2019 Category: Gastroenterology Source Type: research
What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn’s disease activity?
Publication date: Available online 22 February 2019Source: Best Practice & Research Clinical GastroenterologyAuthor(s): Christopher Ma, Robert Battat, Reena Khanna, Claire E. Parker, Brian G. Feagan, Vipul JairathAbstractHistorically, the evaluation of patients with Crohn’s disease (CD) has centered on use of subjective symptom-based assessment. However, patients with CD experience a broad spectrum of non-specific symptoms that may not directly correlate with objective measures of inflammation. Endoscopy has been the gold standard for evaluating the burden and severity of mucosal disease. However, use of ileocolonoscopy ...
Source: Best Practice and Research Clinical Gastroenterology - February 22, 2019 Category: Gastroenterology Source Type: research
IL12/23 or Selective IL23 Inhibition for the Management of Moderate-to-Severe Crohn’s Disease?
Publication date: Available online 19 February 2019Source: Best Practice & Research Clinical GastroenterologyAuthor(s): Christopher Ma, Remo Panaccione, Reena Khanna, Brian G. Feagan, Vipul JairathAbstractThe interleukin (IL)-12 family of cytokines, including IL12 and IL 23, play an important role in driving aberrant Th1 and Th17 immune responses in patients with Crohn’s disease (CD). Targeting this pathway has opened new avenues for therapeutic intervention. The approval of ustekinumab, a monoclonal antibody blocking the common p40 subunit of IL12 and IL23, marked an important evolution in medical management for CD: thi...
Source: Best Practice and Research Clinical Gastroenterology - February 19, 2019 Category: Gastroenterology Source Type: research
What is the role of histopathology in the evaluation of disease activity in Crohn’s Disease?
Publication date: Available online 15 February 2019Source: Best Practice & Research Clinical GastroenterologyAuthor(s): Rish K. Pai, Vipul JairathAbstractAssessment of disease activity is essential for developing and determining appropriate therapy in patients with Crohn’s disease. Currently, clinical and endoscopic treatment targets have been proposed, whereas histologic assessment of disease activity is not recommended in expert guidelines. Histologic assessment of disease activity has emerged as an important tool in ulcerative colitis as persistent histological inflammation is associated with clinical relapse, cortico...
Source: Best Practice and Research Clinical Gastroenterology - February 16, 2019 Category: Gastroenterology Source Type: research
Evolution of treatment targets in Crohn’s Disease
Publication date: Available online 16 February 2019Source: Best Practice & Research Clinical GastroenterologyAuthor(s): Jonathan R. White, Gordon W. Moran, Vipul JairathAbstractCrohn’s disease is a chronic relapsing and remitting inflammatory disorder of the gastrointestinal tract, associated with significantly morbidity due to both symptoms and complications that have a considerable detrimental impact on a patient’s quality of life. An early treat to target approach with disease modifying agents has been shown to significantly improve long term outcomes, demonstrated by a number of therapeutic targets in a number of m...
Source: Best Practice and Research Clinical Gastroenterology - February 16, 2019 Category: Gastroenterology Source Type: research
Targeting anti-fibrotic pathways in Crohn’s Disease – the final frontier?
Publication date: Available online 16 February 2019Source: Best Practice & Research Clinical GastroenterologyAuthor(s): Christopher Ma, Vipul Jairath, Benjamin Click, Simon A. Hirota, Cathy Lu, Claire E. Parker, Florian Rieder, Stenosis Therapy and Anti-Fibrotic Research (STAR) ConsortiumABSTRACTIntestinal fibrosis with stricture formation affects up to half of patients with Crohn’s disease (CD), resulting in impaired quality of life, increased risk of surgical intervention, and associated patient morbidity. The underlying pathophysiologic mechansisms responsible for initiating and perpetuating intestinal fibrosis are co...
Source: Best Practice and Research Clinical Gastroenterology - February 16, 2019 Category: Gastroenterology Source Type: research
The optimal use of blood components in the management of gastrointestinal bleeding
Publication date: Available online 16 February 2019Source: Best Practice & Research Clinical GastroenterologyAuthor(s): Killian Donovan, Simon Stanworth, Vipul JairathAbstractAcute gastrointestinal bleeding accounts for 5,000 deaths per annum in the UK and is the second-most common indication for transfusion of blood components. Transfusion of blood components is integral to management of these patients. Recent years have seen an expansion in the evidence base for their use in this population and this review aims to provide up-to-date guidance on the use of red cells, plasma, platelets, sources of concentrated fibrinogen a...
Source: Best Practice and Research Clinical Gastroenterology - February 16, 2019 Category: Gastroenterology Source Type: research
Editorial Board
Publication date: October–December 2018Source: Best Practice & Research Clinical Gastroenterology, Volumes 36–37Author(s): (Source: Best Practice and Research Clinical Gastroenterology)
Source: Best Practice and Research Clinical Gastroenterology - December 12, 2018 Category: Gastroenterology Source Type: research
Preface “Oesophageal cancer”
Publication date: October–December 2018Source: Best Practice & Research Clinical Gastroenterology, Volumes 36–37Author(s): Bas Wijnhoven, Andrew Davies (Source: Best Practice and Research Clinical Gastroenterology)
Source: Best Practice and Research Clinical Gastroenterology - December 12, 2018 Category: Gastroenterology Source Type: research
Peri-operative patient optimization for oesophageal cancer surgery – From prehabilitation to enhanced recover
Publication date: Available online 30 November 2018Source: Best Practice & Research Clinical GastroenterologyAuthor(s): J. Zylstra, P. Boshier, G.P. Whyte, D.E. Low, A.R. Davies (Source: Best Practice and Research Clinical Gastroenterology)
Source: Best Practice and Research Clinical Gastroenterology - December 5, 2018 Category: Gastroenterology Source Type: research
The management of mid & proximal oesophageal squamous cell carcinoma
Publication date: Available online 30 November 2018Source: Best Practice & Research Clinical GastroenterologyAuthor(s): Ian Wong, Simon LawAbstractDespite the rise in incidence of adenocarcinoma, squamous cell cancer of the oesophagus remains the commonest cell type worldwide and is predominant in the East. Except for very early tumours where endoscopic therapy can be performed with curative intent, in more advanced but potentially curative cancers, treatment for mid and upper third tumours is primarily surgery with extended lymphadenectomy, together with multimodal therapies such as preoperative chemotherapy or chemoradio...
Source: Best Practice and Research Clinical Gastroenterology - December 1, 2018 Category: Gastroenterology Source Type: research
Robot assisted minimally invasive esophagectomy (RAMIE) for esophageal cancer
Publication date: Available online 29 November 2018Source: Best Practice & Research Clinical GastroenterologyAuthor(s): Pieter Christiaan van der Sluis, Richard van HillegersbergAbstract:Worldwide, the standard treatment for locally advanced esophageal cancer with curative intent is perioperative chemotherapy or preoperative chemoradiotherapy followed by open transthoracic esophagectomy (OTE) with gastric conduit reconstruction. Minimally invasive esophagectomy (MIE) was developed to improve the postoperative outcome by reducing the surgical trauma, with comparable short-term oncologic results. However, MIE is a highly com...
Source: Best Practice and Research Clinical Gastroenterology - November 30, 2018 Category: Gastroenterology Source Type: research
Peri-operative patient optimization for oesophageal cancer surgery – From prehabilitation to enhanced recover
Publication date: Available online 30 November 2018Source: Best Practice & Research Clinical GastroenterologyAuthor(s): J. Zylstra, P. Boshier, G.P. Whyte, D.E. Low, A.R. Davies (Source: Best Practice and Research Clinical Gastroenterology)
Source: Best Practice and Research Clinical Gastroenterology - November 30, 2018 Category: Gastroenterology Source Type: research
